单克隆抗体治疗的重症哮喘患者的临床缓解：2年的真实结果

IF 4.3 3区医学 Q1 RESPIRATORY SYSTEM

ERJ Open Research Pub Date : 2024-12-16 eCollection Date: 2024-11-01 DOI:10.1183/23120541.00261-2024

Fred Fyles, Rachel Burton, Amy Nuttall, Hannah Joplin, Laura Watkins, Hassan Burhan

引用次数: 0

摘要

实际数据表明临床缓解是单克隆抗体治疗的一个可行的治疗目标。12个月后持续缓解的证据可用于指导治疗决策。需要进一步的工作来标准化缓解标准。https://bit.ly/4cA6TkG。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ERJ Open Research Medicine-Pulmonary and Respiratory Medicine

CiteScore

6.20

自引率

4.30%

发文量

273

审稿时长

8 weeks

期刊介绍： ERJ Open Research is a fully open access original research journal, published online by the European Respiratory Society. The journal aims to publish high-quality work in all fields of respiratory science and medicine, covering basic science, clinical translational science and clinical medicine. The journal was created to help fulfil the ERS objective to disseminate scientific and educational material to its members and to the medical community, but also to provide researchers with an affordable open access specialty journal in which to publish their work.